CEFAZOLIN FOR INJECTION, USP POWDER FOR SOLUTION

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

CEFAZOLIN (CEFAZOLIN SODIUM)

Διαθέσιμο από:

FRESENIUS KABI CANADA LTD

Φαρμακολογική κατηγορία (ATC):

J01DB04

INN (Διεθνής Όνομα):

CEFAZOLIN

Δοσολογία:

100G

Φαρμακοτεχνική μορφή:

POWDER FOR SOLUTION

Σύνθεση:

CEFAZOLIN (CEFAZOLIN SODIUM) 100G

Οδός χορήγησης:

INTRAVENOUS

Μονάδες σε πακέτο:

100G

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

FIRST GENERATION CEPHALOSPORINS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0109442007; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2015-02-25

Αρχείο Π.Χ.Π.

_CEFAZOLIN FOR INJECTION, USP (Cefazolin for Injection) _
_Page 1 of 26 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CEFAZOLIN FOR INJECTION, USP
Cefazolin for Injection
Powder for Solution, 500 mg and 1 g cefazolin (as cefazolin sodium)
per Vial
Powder for Solution, 10 g and 20 g cefazolin (as cefazolin sodium) per
Pharmacy Bulk Vial
Powder for Solution, 100 g cefazolin (as cefazolin sodium) per
SmartPak
®
Pharmacy Bulk Package
Intramuscular, Intravenous
Antibiotic
Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Initial Authorization:
JAN 28, 1998
Date of Revision:
SEP 13, 2022
Submission Control Number: 263265
_CEFAZOLIN FOR INJECTION, USP (Cefazolin for Injection) _
_Page 2 of 26 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Skin
09/2022
7 WARNINGS AND PRECAUTIONS, Renal
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
5
1.2
Geriatrics
...................................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................